AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
作者信息
Rinella Mary E, Neuschwander-Tetri Brent A, Siddiqui Mohammad Shadab, Abdelmalek Manal F, Caldwell Stephen, Barb Diana, Kleiner David E, Loomba Rohit
机构信息
University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
出版信息
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
2
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的病因、发病机制及治疗
N Engl J Med. 2017 Nov 23;377(21):2063-2072. doi: 10.1056/NEJMra1503519.
3
Is Liver Biopsy Necessary in Patients With Nonalcoholic Fatty Liver Disease?非酒精性脂肪性肝病患者是否需要进行肝活检？
Rev Med Chir Soc Med Nat Iasi. 2016 Jul-Sep;120(3):503-7.
4
Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.非酒精性脂肪性肝炎：更广泛背景下的组织病理学基础
Surg Pathol Clin. 2018 Jun;11(2):267-285. doi: 10.1016/j.path.2018.02.013.
5
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.非酒精性脂肪性肝病和非酒精性脂肪性肝炎：肝移植的相关影响。
Liver Transpl. 2018 Feb;24(2):166-170. doi: 10.1002/lt.25003.
6
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.非酒精性脂肪性肝病的无创评估：当前证据与实践
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307.
7
Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease.生活方式干预对非酒精性脂肪性肝病发病机制的影响。
World J Gastroenterol. 2024 May 28;30(20):2633-2637. doi: 10.3748/wjg.v30.i20.2633.
8
[Research progress of omics biomarkers for nonalcoholic fatty liver disease].[非酒精性脂肪性肝病的组学生物标志物研究进展]
Zhonghua Gan Zang Bing Za Zhi. 2021 Jun 20;29(6):604-608. doi: 10.3760/cma.j.cn501113-20200708-00382.
9
[An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].[2017年美国肝病研究学会非酒精性脂肪性肝病诊断和管理实践指南解读]
Zhonghua Gan Zang Bing Za Zhi. 2017 Sep 20;25(9):687-694. doi: 10.3760/cma.j.issn.1007-3418.2017.09.008.
10
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?非酒精性脂肪性肝病的无创诊断：我们做到了吗？
Metabolism. 2016 Aug;65(8):1087-95. doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2.
引用本文的文献
1
Causal association between macrophage migration inhibitory factor and nonalcoholic fatty liver disease: A two-sample Mendelian randomization study.巨噬细胞移动抑制因子与非酒精性脂肪性肝病之间的因果关联：一项两样本孟德尔随机化研究。
Medicine (Baltimore). 2025 Sep 5;104(36):e44106. doi: 10.1097/MD.0000000000044106.
2
Totum-448 Improves MASLD and Modulates Microbiota in Hamsters: Dose-Response Study and Effects of Supplementation Cessation.托图姆-448改善仓鼠的代谢相关脂肪性肝病并调节微生物群：剂量反应研究及补充停止的影响。
Food Sci Nutr. 2025 Sep 2;13(9):e70904. doi: 10.1002/fsn3.70904. eCollection 2025 Sep.
3
Association between air pollution and risk of non-alcoholic fatty liver disease: an updated meta-analysis.空气污染与非酒精性脂肪性肝病风险之间的关联：一项更新的荟萃分析。
Front Public Health. 2025 Aug 19;13:1606959. doi: 10.3389/fpubh.2025.1606959. eCollection 2025.
4
() rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights.越南劳动年龄成年人中 rs738409 变异与非酒精性脂肪性肝病风险：一项具有代谢见解的病例对照研究
Clin Exp Gastroenterol. 2025 Aug 29;18:191-204. doi: 10.2147/CEG.S532528. eCollection 2025.
5
Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.代谢功能障碍相关脂肪性肝病与肝细胞癌：临床实践中的挑战
Clin Exp Hepatol. 2025 Jun;11(2):105-112. doi: 10.5114/ceh.2025.151618. Epub 2025 Jun 9.
6
Effects of a two-night hospitalization program as a specific health guidance on obesity and cardiovascular disease risk factors.作为一种特定健康指导的两晚住院计划对肥胖和心血管疾病危险因素的影响。
J Gen Fam Med. 2025 May 19;26(5):442-450. doi: 10.1002/jgf2.70031. eCollection 2025 Sep.
7
Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease.营养素作为代谢功能障碍相关脂肪性肝病中的表观遗传调节剂。
World J Hepatol. 2025 Aug 27;17(8):108182. doi: 10.4254/wjh.v17.i8.108182.
8
Myths and facts about the role of diet in metabolic dysfunction-associated steatotic liver disease.关于饮食在代谢功能障碍相关脂肪性肝病中作用的误解与事实
World J Hepatol. 2025 Aug 27;17(8):107909. doi: 10.4254/wjh.v17.i8.107909.
9
Interplay between endocrine disorders and liver dysfunction: Mechanisms of damage and therapeutic approaches.内分泌紊乱与肝功能障碍之间的相互作用：损伤机制与治疗方法
World J Gastroenterol. 2025 Aug 28;31(32):108827. doi: 10.3748/wjg.v31.i32.108827.
10
Cost-effectiveness of transient elastography for liver fibrosis screening in Thai patients with diabetes mellitus.瞬时弹性成像技术用于泰国糖尿病患者肝纤维化筛查的成本效益分析
World J Gastroenterol. 2025 Aug 28;31(32):110333. doi: 10.3748/wjg.v31.i32.110333.
Zotero 插件